Transaction Advisory

Mergers and Acquisitions Sell-side

Experience and stability you can count on

When you choose Alira Health, you’ll benefit from more than two decades of in-depth expertise. Our M&A Sell-side team specializes in serving:

  • A range of companies with €5-250M valuation
  • Cross-border small- and mid-cap deals

Alira Health is a FINRA (USA) and ORIAS (EU) certified firm.

Why choose Alira Health?

As our partner, you’ll also have access to Alira Health’s in-house clinical, regulatory, and market access experts to capture the full value of your assets.

Our recent projects included an advisory role in:

  • A DNA testing company in its sale
  • A specialized contract manufacturer of precision plastic components and devices in its acquisition

Related news

M&A MedTech Pharma
News January 13, 2022
Alira Health Secures an Additional $40M in Funding, Led by Creadev
We announced today the closing of an equity financing in which it raised gross proceeds of US$40 million. We intend to use the funds to invest in solutions that actively engage patients(...)
M&A
Publications August 3, 2021
What You Should Know Before Choosing a Healthcare Transaction Advisory Firm
What’s most important when selecting a firm for your next transaction? Global experience, staff profiles, technical expertise? To learn more read our latest TAD Infographic.
M&A MedTech Pharma
News April 12, 2021
Alira Health Strengthens its Growth Strategy with a $35M Funding, led by Creadev
Alira Health strengthens its growth strategy with a $35M funding, led by Creadev.
M&A Pharma
News December 20, 2020
We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS
We are pleased to announce our role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.
M&A
News November 29, 2020
We Announce our Role as Strategic Advisor to Benvic in the Acquisition of Luc & Bel
We are proud to announce our role as strategic advisor to Benvic in the acquisition of Luc & Bel.
M&A
Publications November 1, 2020
Five Key Success Factors for Managing Transactions in Full Virtual Mode
It is no secret that the COVID-19 pandemic has presented new challenges for businesses, and virtual has become the ‘new normal’, including for transactions.
M&A MedTech
Publications October 10, 2020
Q3 2020 Medical Device Contract Development and Manufacturing M&A Report
Despite the COVID-19 pandemic, M&A activity in the global CDMO industry has been exceptionally strong in 2020 with a record number of transactions completed during the third quarter alone.
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.